SERA PROGNOSTICS INC-A

SERANASDAQ

🏆 #3810 by market capEarnings Aug 12US Equity

$2.00▲ $0.01 (+0.50%)

Live

1h▲ 0.0%

24h▲ 0.5%

7d▲ 0.0%

14d▼ 0.5%

30d▲ 2.6%

1y▼ 10.7%

🏦Market Cap

$76M

Small Cap

📈Revenue Growth (YoY)

+5.2%

Slowing

📊Gross Margin

-191.2%

Thin

💵FCF Margin

-48377.2%

Thin

⚖️P/S Ratio

1340.0x

Expensive

Otter Score

Weak

Trading Snapshot

Day Range: $1.98 – $2.01
52-Week Range: $1.56 – $3.95
Volume: $4.69B
Avg Volume: $5.95B
Shares Outstanding: 38.2M
Next Earnings: Oct 2, 2026

Fundamentals Snapshot

Annual Revenue: $81,000
Last Q Revenue: $14,000
P/E Ratio: -3.1
P/S Ratio: 1340.0x
EPS (TTM): $-0.64
Dividend Yield: 0.00%

Why Investors Own SERA

✓High-growth profile — revenue up +50.6% YoY with expanding US Equity exposure.
✓Healthy economics — 37% gross margin and 14% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$81,000▲ +51.8% YoY

Gross Margin (TTM)

37.3%▲ +0.6% YoY

Operating Income (TTM)

$17,739▲ +51.8% YoY

Free Cash Flow (TTM)

$11,016▲ +51.8% YoY

About SERA PROGNOSTICS INC-A

Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.

🦦